A better understanding of the antigen presentation pathways that lead to CD8 ؉ T cell recognition of HIV epitopes in vivo is needed to achieve better immune control of HIV replication. Here, we show that cross-presentation of very small amounts of HIV proteins from apoptotic infected CD4 ؉ T lymphocytes by dendritic cells to CD8 ؉ T cells is much more efficient than other known HIV presentation pathways, i.e., direct presentation of infectious virus or crosspresentation of defective virus. Unexpectedly, dendritic cells also take up actively antigens into endosomes from live infected CD4 ؉ T lymphocytes and cross-present them as efficiently as antigens derived from apoptotic infected cells. Moreover, live infected CD4 ؉ T cells costimulate cross-presenting dendritic cells in the process. Therefore, dendritic cells can present very small amounts of viral proteins from infected T cells either after apoptosis, which is frequent during HIV infection, or not. Thus, if HIV expression is transiently induced while costimulation is enhanced (for instance after IL-2 and IFN␣ immune therapy), this HIV antigen presentation pathway could be exploited to eradicate latently infected reservoirs, which are poorly recognized by patients' immune systems.
T he prognosis of HIV infection has been greatly improved by highly active antiretroviral treatment. Efficient CD8 ϩ T cell responses are crucial for the development of a protective response against HIV (1) . Specific CD8 ϩ T cells are detected during HIV primary infection, but their responses and phenotypes are altered compared with those found in other primary viral infections that are better controlled by the immune system (2, 3) . Moreover, latently infected cells constitute viral reservoirs that are inaccessible to highly active antiretroviral treatment and do not reach the antigen expression threshold to stimulate directly HIV-specific CD8 ϩ T cells (4) . To obtain better replication control, it would be important to obtain a potent and specific recognition of viral reservoirs by CD8 ϩ T cells.
HIV-specific CD8 ϩ T lymphocytes recognize viral peptides associated with MHC class I molecules on the surface of infected cells. They lyse these cells and produce IFN␥ and other antiviral molecules. To proliferate and differentiate into effector cells, naive CD8 ϩ T lymphocytes require antigen presentation by dendritic cells (DC) (5) . DC are infrequently infected by the virus as compared with CD4 ϩ T lymphocytes (6) . Productive infection may therefore not be the only source of antigen for DC to induce HIV-specific CD8 ϩ T cell responses.
An attractive potential source of HIV antigens in vivo may be the apoptotic infected CD4 ϩ T lymphocytes typically induced by the infection (7) . Apoptotic cells are targeted to specific receptors on macrophages and DC, which phagocytose them (8) . DC have developed specific cross-presentation pathways that allow MHC class I-restricted presentation of the antigens contained in these apoptotic cells to CD8 ϩ T lymphocytes (9, 10) . DC from HIV ϩ patients can activate autologous CD4 ϩ and CD8 ϩ lymphocytes after coculture with infected apoptotic cells (11, 12 ). An alternative source of HIV antigens for DC may be defective viral particles, which can fuse with the plasma membrane and be cross-presented without viral replication (13) . The relative importance of these mechanisms for HIV presentation has never been evaluated.
We have compared these mechanisms on a quantitative basis to assess those that would be relevant in vivo in infected patients. We found that apoptotic infected CD4 ϩ T cell cross-presentation by DC is much more efficient to present HIV antigens to specific CD8 ϩ T cell lines than direct infection or presentation of defective virus particles or proteins. Surprisingly, we found that DC cross-present equally well HIV antigens from live or apoptotic infected CD4 ϩ T lymphocytes, after active antigen acquisition. A good knowledge of the relative importance of these HIV presentation mechanisms in DC is crucial to stimulate them appropriately in infected patients, in order to help the immune system and control HIV replication.
Materials and Methods
Cell Culture. H9 and 8E5 cells were maintained in complete RPMI medium 1640 supplemented with 10% FCS. HIV protein expression was induced in 8E5 cells by phytohemagglutinin (PHA) (Murex Diagnostics, Chatillon, France) and phorbol 12-myristate 13-acetate (Sigma) for 5 days (14) . Primary CD4 ϩ T blasts were obtained from healthy donor peripheral blood mononuclear cells (PBMC; Etablissement Français du Sang, Pitié Salpêtrière, Paris, according to ethical guidelines) after 3 days incubation in 1 g͞ml PHA and 10 units͞ml IL-2 (Roche), then positive CD4 immunomagnetic selection (Miltenyi Biotec, Paris). HIV-specific CD8 ϩ T cell lines were generated by using PBMC of HIV ϩ individuals from cohort studies with the approval of Cochin Hospital's ethics committee as described (15) . DC were differentiated from elutriated monocytes from HLAtyped healthy donors for 5-7 days in granulocyte-macrophage colony-stimulating factor (GM-CSF; Schering-Plough) and IL-4 (PeproTech, London) (15) . DC loading was performed in H-2000 medium (Stemcell Technologies, Neylan, France) with GM-CSF and IL-4.
HLA-A2), Gag 20 -28 (RLRPGGKKK, HLA-A3), and human T-lymphotrophic virus-1 Tax [11] [12] [13] [14] [15] [16] [17] [18] [19] (LLFGYPVYV, HLA-A2) were from Neosystem (Strasbourg, France). The following mAbs were used: anti-MHC class I W6͞32 ascitis (1:100), anti-CD11c (pure or phycoerythrin-labeled) and anti-CD3-FITC (Becton Dickinson), and GaMIg-Cy5 (Caltag, South San Francisco, CA).
Cross-Presentation. H9 or 8E5 cells were irradiated (160 or 40 mJ͞cm 2 at 312 nm, respectively), cultured for 6 h, and then cocultured with DC for 16 h. AZT (200 M; Sigma) was added when specified. Primary CD4 ϩ T cell blasts were irradiated at 20 mJ͞cm 2 24 h after infection (11), cultured for 6 h, and then cocultured overnignt with DC in AZT. After 1 h of culture, 1 g͞ml lipopolysaccharide (LPS) (Escherichia coli, Calbiochem) was added if required. Thereafter, DC were extensively washed, then used as antigen-presenting cells (20,000 per well) in a 6-h IFN␥ enzyme-linked immunospot assay (15) using as effectors CD8 ϩ T cell lines or PBMC. CD4 ϩ T cells were depleted or CD8 ϩ T cells were enriched by using anti-CD4 beads or CD8 T cell isolation kit II, respectively (Miltenyi Biotec). Two or more effector:DC ratios were systematically tested in triplicate. DC class I haplotype was chosen according to CD8 ϩ cell line restriction. In some experiments, apoptotic cells were purified or excluded by using annexin-V-conjugated magnetic microbeads (Miltenyi Biotec), which were then separated by using 10 mM EDTA-PBS. Transwell plates were from Costar. N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK) (Z-VAD, 10 M, Sigma) was added to T cells for 6 h. HIV p24 was quantified in viral stocks or infected cell lysates by ELISA (Innogenetics).
DC Loading. T cells were labeled with PKH67 or PKH26 (Sigma) before irradiation. At the end of the DC͞apoptotic cell coculture, annexin-V-APC (Bender MedSystems, Vienna) and CD11c labeling was performed. In competition assays, DC were incubated with 10 mg͞ml mannan, 500 g͞ml polyG or 10 g͞ml RGD (Arg-Gly-Asp) (all from Sigma) for 40 min at 4°C before coculture with PKH67-labeled live or UV-irradiated H9-HIV cells. After 1 h, cells were washed and stained with anti-CD11c-phycoerythrin in presence of 5 mM EDTA. Cells were then fixed with 1% paraformaldehyde and analyzed by using a FACScalibur flow cytometer and CELLQUEST software (Beckton Dickinson). At least 10,000 viable DC were acquired. For microscopy purposes, cells were settled onto slides in mounting medium (DAKO) and coverslipped after paraformaldehyde fixation. In some experiments, transferrin-Alexa488 (10 g͞ml) or acetylated low density lipoprotein (AcLDL)-Alexa488 (10 g͞ml, Molecular Probes) were added during incubation to define the early and the late endosomal͞lysosomal compartment, respectively. In situ Cell Death Detection Kit, TMR red was from Roche. Samples were acquired by using a TCS SP2 inverted confocal microscope (Leica Microsystems).
Results

DC Loaded with HIV-Infected Apoptotic T Cells Stimulate HIV-Specific
CD8 ؉ Lines. To test cross-presentation of HIV antigens present in apoptotic T lymphocytes, the CD4 ϩ T lymphoma cell line H9 chronically infected by HIV-1 lai was UV-irradiated. Apoptotic cells were isolated by using annexin-V immunomagnetic separation and incubated with monocyte-derived DC from noninfected donors as described in Materials and Methods. As shown in Fig. 1A , an HLA-A2-restricted HIV-1 reverse transcriptase (RT)-specific T cell line recognized the epitope on the surface of DC. Other CD8 ϩ T cell lines specific for the HLA-A2-and HLA-A3-restricted Nef-and Gag-derived epitopes were also stimulated after presentation by DC loaded with apoptotic H9-HIV cells ( Fig. 1 B-D) . This recognition was restricted by MHC class I molecules because it was blocked by an anti-class I mAb, and only CD8 ϩ T cells secreted IFN␥, as assessed by intracellular cytokine flow cytometry (not shown). In addition, recognition depended on DC haplotype (Fig. 1B) , excluding direct viral presentation by apoptotic H9-HIV cells.
Monocyte-derived DC do not constitute a preferential target for HIV, and only minor amounts of viral RNA are produced when they are infected in vitro (17, 18) . Nevertheless, in our experimental system, DC were incubated overnight with HIVproducing cells; they could be infected and generate sufficient amounts of HIV epitopes to be presented to CD8 ϩ HIV-specific lines. To exclude direct viral presentation, DC and apoptotic cells were cocultured in the presence of AZT to block replication (19) . DC presented HIV antigens in the absence of productive viral particle infection (Fig. 1C) . Nonproductive infection of DC by defective viral particles can also yield antigen presentation to an HIV-specific CD8 ϩ clone (13) . To investigate this potential mechanism, apoptotic cells were incubated in the upper compartment of a 0.45-m transwell plate, allowing virion and soluble protein passage onto DC in the lower compartment, as measured by Bradford and Gag p24 ELISA tests, but preventing DC͞apoptotic cell contact. In these conditions no specific response was detected (Fig. 1C ), indicating that a contact or high proximity between DC and apoptotic cells was required for antigen uptake. These results suggested that viral infection, defective virion, or soluble antigen uptake are poorly efficient viral antigen acquisition mechanisms for MHC class I-restricted presentation by DC, compared with internalization of apoptotic debris. To study cross-presentation in the absence of infective virions, we used 8E5 cells, which are infected with an RTdefective HIV-1 lai variant and cannot produce infective viral particles, but produce low amounts of viral proteins after activation. The mean amount of p24 protein was 27 Ϯ 36 ng of p24 per million cells for H9-HIV and 2 Ϯ 1.5 pg of p24 per million cells for activated 8E5 cells. Activated, irradiated 8E5 cells cocultured with DC induced efficient antigen presentation (Fig. 1D) . These data show that DC actually cross-present MHC class I-restricted HIV antigens from apoptotic infected T cell lines to specific CD8 ϩ T lymphocytes, in the absence of direct infection or of viral particles, even when low amounts of viral proteins are available. 
Cross-Presentation of HIV Antigens from Apoptotic T Cells Is More Efficient Than Direct Presentation or Presentation of Nonreplicating
Virus. The different mechanisms of HIV antigen uptake and presentation mentioned above were compared quantitatively, by using p24 measurement in viral isolates or in apoptotic infected T cells before incubation with DC. Different amounts of HIV-1 lai , replication competent or not (without or with AZT), or apoptotic T cells (with AZT to avoid direct presentation) were incubated overnight with DC. As seen in Fig. 3, low To test the dependence on apoptotic death of HIV crosspresentation, infected and non-infected H9 cells were labeled with the PKH67 cell membrane dye and cocultured with DC after being UV-irradiated or not. As shown in Fig. 4A , most of the DC (70-96% depending on the experiment) acquired PKH67 labeling, and neither the percentage of PKH67 ϩ DC nor the fluorescence intensity was decreased if target cells were not previously irradiated. At 4°C, PKH67 acquisition was decreased to 19-24% of weakly positive DC, indicating that DC actively acquired material from live as well as apoptotic T cells (not shown). HIV-stimulated DC might have induced apoptosis in T lymphocytes, then phagocytosed the resulting debris (21) . However, treatment of the cocultures with the pan-caspase inhibitor Z-VAD (22) did not reduce labeled material uptake (Fig. 4A) . Apoptosis may also occur independently of caspases, but, in this experimental setting with low DC:H9 cell ratios, DC did not induce detectable apoptosis in nonirradiated cells anytime (Fig.  4 B and C; see also Fig. 4D, live) . When live H9-HIV cells were cocultured with DC in the presence of Z-VAD, intimate DC-T contact and no T cell apoptosis were observed by confocal microscopy (Fig. 4D ). All these data show that apoptosis induction is not required for antigen transfer. Material transfer from T lymphocytes into DC was visualized (Fig. 7 , which is published as supporting information on the PNAS web site): PKH67-labeled membrane patches and intracellular vesicles were found in DC, and CD3 surface-labeling stained not only T lymphocytes, but also patches on DC. Similar patterns were obtained when H9-HIV cells were labeled with carboxyfluorescein diacetatesuccinimidyl ester (data not shown), a dye that labels cytoplasmic proteins, indicating that transfer is not restricted to plasma membrane-associated material. Equivalent results were obtained by using live HIV lai -infected primary CD4 ϩ T cell blasts: PKH67-labeled material was found in 26 Ϯ 6% of DC at 20 min and 50 Ϯ 14% at 2 h. Clear vesicular aspects were evidenced in half of the cells that had incorporated PKH67-stained material. A majority of PKH-positive vesicles colocalized with transferrin (64 Ϯ 5%) or AcLDL (75 Ϯ 7%, Fig. 4E ). Therefore, live cell material was effectively internalized into DC and undergoes Fig. 2 . DC cross-present a viral epitope from CD4 ϩ primary lymphocytes infected with a WT HIV isolate. DC were cultured with irradiated CD4 ϩ T cell blasts infected with different amounts of a primary HIV isolate in the presence or absence of LPS and tested by using an anti-Nef 73-82 CD8 ϩ line as in Fig. 1 . This experiment was carried out in the presence of AZT. classical trafficking from early (transferrin-positive) to late endosomes (positive for AcLDL).
Several receptors have been implicated in apoptotic or live cell material uptake by DC (23) (24) (25) . Both live and apoptotic cellassociated material uptake were inhibited by polyG and fucoidan, and not by mannan, Arg-Gly-Asp (RGD), or Arg-GlyAsp-Ser (RGDS) (Fig. 4F and not shown), indicating uptake mediated by scavenger receptors and not mannose receptors or ␣ integrins.
To determine whether this transfer from live cells led to HIV antigen presentation, DC were cultured overnight with irradiated or live Z-VAD-treated H9-HIV cells. Amazingly, the HIV-specific CD8 ϩ cell line recognized live infected H9 cells with a dose-response curve entirely superimposed to that of apoptotic cells (Fig. 5A) . Similar results were obtained with Z-VAD untreated cells (data not shown). Live H9-HIV cells were not recognized in the absence of DC (Fig. 5A Inset) . When DC-T contact was blocked by using a 0.45-m transwell, crosspresentation was prevented (Fig. 8A , which is published as supporting information on the PNAS web site), despite passage of particles with a size similar to that of 100-to 430-nm beads (Fig. 8B) . Consistently with previous results, a three-log excess of free virus over the maximal viral protein concentration in infected cells was unable to induce a detectable CD8 ϩ T cell stimulation (Fig. 5A) . These data indicate that HIV antigen can be transferred from both apoptotic and live cells to DC, and that both mechanisms are equally efficient for MHC class I-restricted presentation. Moreover, cross-presented HIV antigens from live infected cells were recognized by circulating CD8 ϩ T cells isolated from HIV-infected patients (Fig. 5B) , adding more in vivo relevance to these results.
Discussion
The data presented here show that antigens from not only apoptotic, but also live, infected CD4 ϩ T cells can be presented by DC much more efficiently than live virus or replicationdeficient viral particles by using quantitative tests. This crosspresentation was restricted by DC MHC class I molecules, occurred in the absence of viral replication or viral particles, and required contact between DC and infected T cells. Antigen transfer from nonirradiated CD4 ϩ lymphocytes to DC and subsequent cross-presentation occurred from live T cells and not from contaminating apoptotic cells, either present as a minor population in the culture or secondarily induced by HIVexposed DC. Indeed, it was not prevented by a pan-caspase inhibitor because in these conditions apoptosis was not induced by DC anytime during coculture, and the dose-response curves obtained with irradiated and nonirradiated CD4 ϩ -infected cells were superimposable. Therefore, we demonstrate crosspresentation of infectious antigens from live antigen-donor cells as in an elegant model using OVA-expressing recombinant vaccinia viruses (26) . We questioned the mechanism of antigen acquisition from live infected cells and the potential relevance of these different presentation mechanisms for HIV infection.
Different mechanisms for antigen exchange between T lymphocytes and DC are possible: exosome (27) or microparticle transfer (28) , or antigen uptake from whole cells (29, 30) . Antigen cross-presentation was blocked by a 0.45-nm membrane, despite demonstrated passage of particles with sizes compatible with that of exosomes (50-90 nm), or microvesicles generated by H9-HIV cells (50-500 nm) (31) . If these particles were the major source of HIV antigens for DC cross-presentation, then their transfer would not need close DC:T cell contact, as those found by microscopy. The nibbling mechanism, implying cellassociated material exchange, has been described for antigen transfer from DC, macrophages, B cells, and activated T lymphocytes to monkey DC, allowing cross-presentation of a tumor antigen to CD8 ϩ lymphocytes (30) . Here, capture of both live and apoptotic cell material seemed dependent on scavenger receptors, and not on mannose-binding lectins or integrins. Redundant pathways difficult to inhibit by a single antibody may be involved. This process is distinct from the reverse acquisition of membrane material from antigen-presenting cells by T cells, which occurs after immunological synapse formation, only during cognate interaction between the T cell receptor and epitopeloaded MHC molecules (32, 33) . Interaction between DC and T lymphocytes has already been reported in the absence of cognate antigen or relevant MHC expression in DC (34) . This interaction, characterized as an antigen-independent synapse, induces signaling in T lymphocytes, as well as in DC (35) that may stimulate nibbling. HIV antigens may be recruited at the site of the synapse, as occurs in interactions between HIV-infected DC and T cell lines (36) .
The different MHC class I-restricted presentation pathways that have been described for HIV antigens in DC, i.e., classical presentation after direct infection and cross-presentation after defective virus entry (13) or after phagocytosis of infected apoptotic CD4 ϩ T lymphocytes (11, 12) , had never been compared quantitatively. Our experiments attempted to reproduce in vivo conditions by using CD8 ϩ T cell lines with a relative low avidity or even CD8 ϩ cells purified from HIV ϩ patient PBMC. We also validated the results obtained with chronically infected immortalized CD4 ϩ T cells using primary CD4 ϩ T lymphocytes together with a primary viral isolate. The role of apoptosis in enhancing cross-presentation has up to now been extensively compared with that of necrosis (10, 37), but not quantitatively with that of live cell-associated antigen transfer. The equivalent efficacy of apoptotic or live cell cross-presentation in the present study may be coincidental because the two pathways presumably use different and redundant receptors to internalize antigens into DC (23, 24) .
We show that apoptotic or live cell cross-presentation needs very low amounts of HIV proteins to reach the threshold for efficient CD8 ϩ T cell stimulation. Conversely, HIV epitope presentation after direct infection of DC was not detectable, even with high amounts of replicative virus. Efficient presentation after DC infection by live or defective virus probably needs recognition by high-avidity CD8 ϩ T clones (13) whereas it was not found in another study using PBMC from patients (11) . Therefore, in vivo, cross-presentation should allow recognition of cells expressing very low amounts of viral proteins by naive or average-avidity memory CD8 ϩ T lymphocytes.
Cross-presentation can induce immunity or tolerance, depending on the environment and the activation state of the DC. In the absence of CD40-CD40L costimulation, it leads to tolerance or even suppression of immune responses (10, 38, 39) . A striking correlation was shown between the frequency of cytotoxic T lymphocytes specific for vinculin, an antigen overexpressed in apoptotic cells, and the proportion of peripheral apoptotic CD40L ϩ T cells in HIV-infected patients, implying that vinculin is cross-presented by DC from CD40L ϩ T cells (22) . In the present study, the apparent lack of requirement for DC maturation stimuli may be related to the use of HIV-specific CD8 ϩ T cell lines, which need less costimulation than PBMC. It may also be related to the HIV-and apoptosis-independent induction of DC maturation by primary CD4 ϩ T cell blasts. In our hands, the proportion of CD83 ϩ (mature) cells (Fig. 6 ) and CD40 expression (not shown) increased when DC were incubated with primary CD4 ϩ T cell blasts, whether these blasts were apoptotic or not, independently of HIV infection. In former studies, when PBMC from HIV-infected patients and not T cell lines were used, soluble CD40L or CD4 ϩ T cell help or LPS were indeed required (11) . From all these data, and because HIV infects predominantly activated lymphocytes (40) , it is likely that, in vivo, live and apoptotic HIV-infected T lymphocytes can supply antigens and costimulation signals for MHC class I-restricted presentation by DC and thus immunostimulation. On the other hand, they may induce tolerance, depending on HIV infection stage, because, in HIV patients with low CD4 counts, triggering of CD40L on T cells is impaired (41) . Finally, the outcome of live infected cell cross-presentation might be stimulation or tolerance and needs to be further explored.
In vivo, the infection route was shown to influence the nature of the pathway used for MHC class I-restricted presentation (42) . This pathway may depend on the cell types encountered by the antigens. DC are required for CD8 ϩ lymphocyte cross-priming in vivo, even after infection with bacteria infecting macrophages (5) . Cross priming after HSV-1 s.c. infection occurs rapidly in lymph nodes in the absence of local virus, suggesting rapid and efficient antigen uptake and presentation by DC (43) . This activity requires viral protein synthesis, indicating that DC capture antigens from productively infected cells, but the model did not discriminate whether donor-infected cells were alive or apoptotic. Cross-presentation of live cell-associated antigens might allow the development of an early immune response at the first stages of HIV infection, before apoptosis is massively induced. Moreover, HIV antigen acquisition from live cells by DC could be an efficient mechanism to induce recognition of very low amounts of viral proteins and destruction of latent viral reservoirs. This mechanism could probably be enhanced by using either granulocyte colony-stimulating factor to promote limited viral production in resting T lymphocytes and macrophages (44, 45) , or IL-2 to promote viral production in T cells and restore T cell help (46, 47) , combined with IFN␣ to enhance crosspresentation, and CD4 ϩ T helper 1 and CD8 ϩ T cell effector functions (48, 49) , during highly active antiretroviral treatmentstructured interruptions. Thus, eradication of reservoirs might be obtained.
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